Featured Publications
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree timesEvaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting
Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, Wilkinson ST. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. JAMA Psychiatry 2022, 79: 736-738. PMID: 35544190, PMCID: PMC9096687, DOI: 10.1001/jamapsychiatry.2022.1074.Peer-Reviewed Original ResearchAdvanced training in interventional psychiatry
Nikayin S, Taylor JJ, Ostroff RB. Advanced training in interventional psychiatry. Journal Of The Neurological Sciences 2021, 434: 120093. PMID: 34974201, DOI: 10.1016/j.jns.2021.120093.Peer-Reviewed Original ResearchThe Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents
Colloca L, Nikayin S, Sanacora G. The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents. JAMA Psychiatry 2023, 80: 867-868. PMID: 37405764, PMCID: PMC10868530, DOI: 10.1001/jamapsychiatry.2023.1412.Peer-Reviewed Original Research
2024
Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.Peer-Reviewed Original ResearchConceptsBipolar depressionAcute seriesRisk of affective switchDiagnosis of bipolar depressionRefractory bipolar depressionAcute phaseMADRS scoreAffective switchIntranasal esketamineManic episodesBipolar disorderCohort of patientsAttending psychiatristsSource of morbidityEsketamineSample of patientsIV ketamineMaintenance treatmentDepressionClinical responseHeightened riskClinical outcomesMania/hypomaniaKetamineKetamine/esketamineKetamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Jha M, Wilkinson S, Krishnan K, Collins K, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew S, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression. JAMA Network Open 2024, 7: e2417786. PMID: 38916891, PMCID: PMC11200139, DOI: 10.1001/jamanetworkopen.2024.17786.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionQIDS-SR16 scoresElectroconvulsive therapy groupElectroconvulsive therapyQIDS-SR16Measure of premorbid intelligencePosttraumatic stress disorder diagnosisTrial of electroconvulsive therapyNonpsychotic depressive episodeImpaired memory recallAssociated with differential improvementStress disorder diagnosisIntravenous ketamineEnd-of-treatment visitInfusion of ketamineMADRS scorePremorbid intelligenceResistant depressionDepressive episodeMeasures mixed-effects modelsFalse discovery rate adjustmentDisorder diagnosisMemory recallSevere depressionDifferential improvementDepression - Advanced Treatments for Treatment-Resistant Depression.
Cristancho M, Fava M, Ingelfinger J, Nikayin S, Sanacora G. Depression - Advanced Treatments for Treatment-Resistant Depression. New England Journal Of Medicine 2024, 390: e44. PMID: 38810184, DOI: 10.1056/nejmp2310181.Peer-Reviewed Original ResearchDepression - Understanding, Identifying, and Diagnosing.
Anderson E, Crawford C, Fava M, Ingelfinger J, Nikayin S, Sanacora G, Scott-Vernaglia S, Teel J. Depression - Understanding, Identifying, and Diagnosing. New England Journal Of Medicine 2024, 390: e41. PMID: 38692291, DOI: 10.1056/nejmp2310179.Peer-Reviewed Original Research
2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indications
2022
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion On Drug Safety 2022, 21: 777-787. PMID: 35416105, DOI: 10.1080/14740338.2022.2066651.Peer-Reviewed Original ResearchConceptsLong-term safetyClinical trialsRacemic ketamineLong-term safety effectsRapid-acting antidepressant effectsLower urinary tract symptomsKetamine/esketamineTreatment-resistant depressionUrinary tract symptomsCommon side effectsTreatment of depressionLong-term impairmentElevated heart ratePhase three clinical trialsTract symptomsAntidepressant effectsBlood pressureIncreased riskBladder pathologyEsketamineHeart ratePsychiatric disordersSide effectsCognitive impairmentHigh dosesCatatonia After COVID-19
Nikayin S, Chaffkin J, Ostroff RB. Catatonia After COVID-19. Journal Of Ect 2022, 38: e43-e44. PMID: 35220361, PMCID: PMC9426344, DOI: 10.1097/yct.0000000000000838.Peer-Reviewed Original Research
2021
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk
Nikayin S, Sanacora G. Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk. CNS Drugs 2021, 35: 1069-1079. PMID: 34491545, DOI: 10.1007/s40263-021-00851-8.Peer-Reviewed Original ResearchConceptsMajor depressive disorderDepressive disorderSuicidal ideationFirst large-scale trialKetamine/esketamineTreatment of patientsRole of ketamineSerious suicidal thoughtsActive suicidal ideationLarge-scale trialsAcute settingImminent riskClinical trialsPivotal studiesEsketamineClinical meaningfulnessRecent approvalPatientsSuicidal thoughtsSuicide riskNovel therapeuticsDisordersTrialsDepressed individualsIdeation
2020
Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review
Rabiee A, Ximenes R, Nikayin S, Hickner A, Juthani P, Rosen RH, Garcia‐Tsao G. Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review. Liver International 2020, 41: 6-15. PMID: 32998172, DOI: 10.1111/liv.14680.Peer-Reviewed Original ResearchConceptsHealth-related qualityPoor HRQOLMuscle crampsHepatic encephalopathyPoor sleepSystematic reviewPoor health-related qualityPatient-reported outcomesPoor social supportPatient-centered careFull-text screeningAdult patientsPoor HRQoL.Cirrhosis etiologyHRQoLCirrhosisGeneric instrumentsEligibility criteriaCognitive impairmentPatientsMajority of studiesIdentified factorsCrampsDemographic factorsFrailty
2018
Executive Summary
Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Executive Summary. Critical Care Medicine 2018, 46: 1532-1548. PMID: 30113371, DOI: 10.1097/ccm.0000000000003259.Peer-Reviewed Original ResearchClinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical Care Medicine 2018, 46: e825-e873. PMID: 30113379, DOI: 10.1097/ccm.0000000000003299.Peer-Reviewed Original ResearchConceptsAgitation/sedationManagement of painClinical practice guidelinesAdult patientsPractice guidelinesPractice statementsCritical illness survivorsTreatment of painBest practice statementsCritical care medicineInternational expertsICU survivorsRecommendations AssessmentIll adultsClinical caveatsGuideline groupSection groupImproved outcomesSleep disruptionCare medicineDeliriumPainClinical relevanceSedationGuideline development
2017
Validity of the Posttraumatic Stress Symptoms-14 Instrument in Acute Respiratory Failure Survivors
Parker AM, Nikayin S, Bienvenu OJ, Needham DM. Validity of the Posttraumatic Stress Symptoms-14 Instrument in Acute Respiratory Failure Survivors. Annals Of The American Thoracic Society 2017, 14: 1047-1048. PMID: 28355099, PMCID: PMC5566312, DOI: 10.1513/annalsats.201702-112le.Peer-Reviewed Original Research
2016
Depressive Symptoms After Critical Illness
Rabiee A, Nikayin S, Hashem MD, Huang M, Dinglas VD, Bienvenu OJ, Turnbull AE, Needham DM. Depressive Symptoms After Critical Illness. Critical Care Medicine 2016, 44: 1744-1753. PMID: 27153046, PMCID: PMC7418220, DOI: 10.1097/ccm.0000000000001811.Peer-Reviewed Original ResearchConceptsDepressive symptomsICU survivorsHospital AnxietyRisk factorsCochrane Controlled Trials RegistryDepression Scale depression subscaleImportant depressive symptomsControlled Trials RegistryDuplicate independent reviewAllied Health LiteratureCritical illnessHospital dischargeTrials RegistryPsychologic morbidityPooled changeCumulative IndexEligible articlesHealth LiteratureSymptomsNatural historyDistress symptomsPrevalenceThreshold scoreTime pointsMonthsAnxiety symptoms in survivors of critical illness: a systematic review and meta-analysis
Nikayin S, Rabiee A, Hashem MD, Huang M, Bienvenu OJ, Turnbull AE, Needham DM. Anxiety symptoms in survivors of critical illness: a systematic review and meta-analysis. General Hospital Psychiatry 2016, 43: 23-29. PMID: 27796253, PMCID: PMC5289740, DOI: 10.1016/j.genhosppsych.2016.08.005.Peer-Reviewed Original ResearchConceptsICU survivorsCritical illnessAnxiety symptomsPsychiatric symptomsPhysical rehabilitationDepression Scale-Anxiety subscaleSeverity of illnessAdult ICU survivorsLength of stayPotential risk factorsAnxiety symptom prevalenceSubset of studiesSymptom prevalenceHospital AnxietyRisk factorsICU diariesMerit further investigationSame patientDelusional experiencesSystematic reviewSymptomsAnxiety scoresIllnessSurvivorsAdmission
2013
Psychiatric aspects of primary immunodeficiency diseases: the parental study.
Abolhassani H, Aghamohammadi A, Pourjabbar S, Salehi Sadaghiani M, Nikayin S, Rabiee A, Imanzadeh A, Mahmmoodi Gharaei J, Arbabi M, Rezaei N. Psychiatric aspects of primary immunodeficiency diseases: the parental study. Iranian Journal Of Allergy Asthma And Immunology 2013, 12: 176-81. PMID: 23754357.Peer-Reviewed Original ResearchConceptsPID patientsPsychiatric aspectsComplications of treatmentPrimary immunodeficiency diseasesLong-term illnessPID groupPatient complaintsPsychiatric effectsImmunodeficiency diseaseSide effectsDisease consistPatientsIncurable diseaseReliable questionnaireSuccessful managementTotal scoreParental studiesDiseaseLonger durationSignificant differencesChildrenPsychological counselingComplaintsAnxietyGroup